ESOT Congress exhibition area

SUPPORTERS

ESOT gratefully acknowledges the support of our Corporate Partners, Congress Supporters and Exhibitors

___________________________________________________________________________
ESOT GOLD CIRCLE

Astellas

___________________________________________________________________________
ESOT EDUCATION CIRCLE

Sandoz

___________________________________________________________________________
ESOT SILVER CIRCLE

Chiesi | Novartis | Roche

___________________________________________________________________________
ESOT2019 SUPPORTERS

Organ Recovery Systems

___________________________________________________________________________
ESOT2019 EXHIBITORS

Atara Biotherapeutics | CSL Behring | Dr. Franz Köhler Chemie | Fresenius Medical Care | IGL | Immudex | Mallinckrodt PharmaceuticalsOrgan Recovery Systems | Neovii

 

ASTELLAS
Atara Biotherapeutics

Atara Biotherapeutics, Inc. (@Atarabio) is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. Atara’s most advanced T-cell immunotherapy, tab-cel®, is in Phase 3 development for patients with Epstein-Barr virus associated post-transplant lymphoproliferative disorder, as well as other EBV-associated hematological malignancies and solid tumors, including nasopharyngeal carcinoma.

CHIESI

Based in Parma, Italy, Chiesi Farmaceutici is an international research-focused Healthcare Group, with over 80 years of experience in the pharmaceutical industry, present in 26 countries. Chiesi researches, develops and markets innovative drugs in the respiratory therapeutics, specialist medicine and rare disease areas. Its R&D organisation is headquartered in Parma (Italy), and integrated with 6 other key R&D groups in France, the USA, the UK, Sweden and Denmark to advance Chiesi’s pre-clinical, clinical and registration programmes. Chiesi employs nearly 5,000 people. Chiesi entered in the solid organ transplant arena with Envarsus®,  a prolonged-release tacrolimus formulation with a distinctive PK profile.

CSL Behring logo CSL Behring

CSL Behring is a global biotherapeutics leader driven by our promise to save lives. We meet patients’ needs using the latest technologies to develop and deliver innovative biotherapies that are used to treat serious and rare conditions such as coagulation disorders, primary immune deficiencies, hereditary angioedema and inherited respiratory disease.

  Dr. Franz Köhler Chemie

Dr. Franz Köhler Chemie GmbH is an independent, family owned company with representations world-wide. Since 1959 we are a reliable partner for transplant and cardiac surgery centers and the ICU. Our portfolio includes anesthetics, medical devices, electrolytes, contrast-media, antidotes, organ-protective and cardioplegic-solutions. The company is world-wide known for its Custodiol®.

Fresenius Medical Care

Therapeutic Apheresis of Fresenius Medical Care is dedicated to provide extracorporeal therapies with (semi-)selective adsorber and filter. Thereby harmful pathogens causing various autoimmune diseases or metabolic disorders can be effectively depleted from the blood. These alternative treatment methods can be beneficial in acute or chronic disease conditions.

IGL

IGL, consists of a network of subsidiaries located worldwide. This means we are never far from our customers and so can help them to meet their local challenges. We design, manufacture, and market proprietary and generic products for organ preservation devices. Our products are essential for the success of organ transplantations.

IMMUDEX

Based in Copenhagen, Denmark, Immudex manufactures MHC Dextramers for the detection of antigen-specific T cells in life science research, in vitro diagnostics, and the development of immunotherapeutics and vaccines. Under an agreement with the US Cancer Immunotherapy Consortium (CIC) and the European Cancer Immunotherapy Consortium (CIMT), Immudex also provides MHC Multimer and Elispot proficiency panel services worldwide.

Mallinckrodt Pharmaceuticals logo Mallinckrodt Pharmaceuticals (Therakos (UK) Ltd)

Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Mallinckrodt is the only provider of integrated systems for the delivery of Extracorporeal Photopheresis (ECP).

Neovii

Neovii is an independent, global biopharmaceutical company with a patient-focused mission to develop and bring to market novel life-transforming therapies to improve the outcomes in transplantation medicine, hemato-oncological and immune disorders. Neovii’s global headquarters are located in Rapperswil, Switzerland and has presence in over 50 countries worldwide.

NOVARTIS

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2016, the Group achieved net sales of USD 48.5 billion, while R&D throughout the Group amounted to approximately USD 9.0 billion (USD 8.4 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 118,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world.

 

Organ Recovery Systems logo Organ Recovery Systems

Organ Recovery Systems, the global market-leading provider of organ preservation products and services, supports 286 transplant programs in 39 countries with the LifePort® Kidney Transporter and preservation solutions: SPS-1® (UW Solution) and KPS-1® (UW machine perfusion solution). The LifePort Liver Transporter is undergoing regulatory review in the US and EU.

ROCHE

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche’s transplant treatments are designed to support the long-term survival of transplanted organs.

SANDOZ

At Sandoz, we discover new ways to improve and extend people’s lives. We pioneer novel approaches to help people around the world access high-quality medicine. To achieve this, we pursue an integrated access strategy that focuses our work on improving access to medicines, access to medical information and access to medical capacity building, which includes efforts to provide and support appropriate training for healthcare professionals. In 2015, our products reached an estimated 520 million patients and our aspiration is to reach 1 billion people.